Cargando…
A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
There is a concern on the risk of thyroid cancer associated with glucagon-like peptide-1 (GLP-1) analogs including liraglutide and exenatide. In this article, we review related experimental studies, clinical trials and observational human studies currently available. In rodents, liraglutide activate...
Autores principales: | Chiu, Wei-Yih, Shih, Shyang-Rong, Tseng, Chin-Hsiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368340/ https://www.ncbi.nlm.nih.gov/pubmed/22693487 http://dx.doi.org/10.1155/2012/924168 |
Ejemplares similares
-
Diabetes and Thyroid Cancer Risk: Literature Review
por: Shih, Shyang-Rong, et al.
Publicado: (2012) -
Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
por: Lisco, Giuseppe, et al.
Publicado: (2023) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017) -
Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023) -
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
por: Kang, Yu Mi, et al.
Publicado: (2016)